Closing Strong: Quince Therapeutics Inc (QNCX) Ends at $2.69, Up 0.37 from Last Close

Kevin Freeman

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

After finishing at $2.68 in the prior trading day, Quince Therapeutics Inc (NASDAQ: QNCX) closed at $2.69, up 0.37%. In other words, the price has increased by $0.37 from its previous closing price. On the day, 0.61 million shares were traded. QNCX stock price reached its highest trading level at $2.815 during the session, while it also had its lowest trading level at $2.63.

Ratios:

Our goal is to gain a better understanding of QNCX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.12. In the meantime, Its Debt-to-Equity ratio is 16.97 whereas as Long-Term Debt/Eq ratio is at 0.34.

Upgrades & Downgrades

In the most recent recommendation for this company, Citizens JMP on August 05, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $9.

On March 24, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $10.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 26 ’25 when LUCA BENATTI bought 50,000 shares for $3.46 per share.

Benatti Luca sold 50,000 shares of QNCX for $173,500 on Dec 26 ’25. The Director now owns 39,179 shares after completing the transaction at $3.47 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, QNCX now has a Market Capitalization of 149783200 and an Enterprise Value of 141488208.

Stock Price History:

The Beta on a monthly basis for QNCX is 1.24, which has changed by 0.5549133 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, QNCX has reached a high of $4.55, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is -4.78%, while the 200-Day Moving Average is calculated to be 49.12%.

Shares Statistics:

The stock has traded on average 667.77K shares per day over the past 3-months and 557510 shares per day over the last 10 days, according to various share statistics. A total of 54.49M shares are outstanding, with a floating share count of 48.34M. Insiders hold about 13.18% of the company’s shares, while institutions hold 20.78% stake in the company. Shares short for QNCX as of 1765756800 were 2064545 with a Short Ratio of 3.09, compared to 1763078400 on 1365905. Therefore, it implies a Short% of Shares Outstanding of 2064545 and a Short% of Float of 4.14.

Earnings Estimates

. The current rating of Quince Therapeutics Inc (QNCX) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.15 and low estimates of -$0.23.

Analysts are recommending an EPS of between -$1.03 and -$1.15 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$0.72, with 4.0 analysts recommending between -$0.11 and -$1.24.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.